



04-2581

PCT
#2

"Express Mail Post Office mailing label number EL559725913US Date of Deposit April 24, 2001
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

BulienOlomis

Printed Name

Bruce Thomas

Signature

PATENT APPLICATIONIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Fatima Emitsel Yakubu-Madus, et al.)
For : SYNERGISTIC USE OF THIAZOLIDINEDIONES)
WITH GLUCAGON-LIKE PEPTIDE-1 AND)
AGONISTS THEREOF TO TREAT METABOLIC)
INSTABILITY ASSOCIATED WITH NON-)
INSULIN DEPENDENT DIABETES)
Application No.: PCT/US00/15548)
Docket No. : X-11921)

RECEIVED

20 MAY 2001

*Legal Staff
International Division*PETITION TO REVIVE UNDER 37 C.F.R. §1.137 (b)

Attention: Office of Petitions
Assistant Commissioner for Patents
Box DAC
Washington, D. C. 20231

Sir:

The above-identified application was abandoned for failure to prosecute. Applicants respectfully state that the delay was unintentional and petition that the application be revived and reinstated as a pending application. Applicants further state that the entire delay in filing the required reply from the due date for the reply until the filing of a grantable petition pursuant to 37 CFR 1.137(b) was unintentional.

A proposed application accompanies this petition.

04/30/2001 LLANDGRA 00000006 050840 09830323


01 FC:141

1240.00 CH Please charge the amount of \$1,210 [the fee under 1.17(m)] to cover the cost of this Petition and charge any additional fees which may be required by this or any other related paper, or credit any overpayment to Deposit Account No. 05-0840]. An original and two copies of this paper are enclosed.

Serial No. X-11921

Applicants request favorable action on this petition.

Respectfully submitted,



Mark J. Stewart
Attorney for Applicants
Registration No. 43,936

Phone: 317-276-0280

Eli Lilly and Company
Patent Division/MJS
Lilly Corporate Center
Indianapolis, Indiana 46285

April 24, 2001